PATENT CLAIM ANALYSIS

Application Number: 16018244
Application Type: Utility
Filing Date: 2018-06
Publication Date: 2018-10
Patent Classification: ["424", "135100"]

Abstract:
A method is provided for reducing the treatment burden for patients who have an intraocular neovascular disorder, the method comprising administering a therapeutically effective amount of VEGF antagonist on a dosing schedule that includes treatment intervals of 8 and/or 12 weeks.

Claim (Index 3):
The method of  claim 2 , wherein each dose of the VEGF antagonist is administered as a 50 \u03bcL intravitreal injection.

Metadata:
- Claim Count in Document: 12.0
- Percentile: 94.0
- Lexical Diversity: 1.16216
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['14934731', '13940370', '14972560', '15471506', '13140411']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7426244783466446
- 35 USC 102 Novelty (BERT): 0.5622563921050477
- Combined Prediction Score: 0.7245876697224849
- Mean Citation Score: 284.5033160000001
- Max Citation Score: 449.12402
- Similarity Product: 352.692228155334

Labels:
- Claim Label 101: 1
- Claim Label 102: 0
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 0
- Label 101 Adjusted: 1

Dataset: test